NZ748502A - Oxaborole esters and uses thereof - Google Patents
Oxaborole esters and uses thereofInfo
- Publication number
- NZ748502A NZ748502A NZ748502A NZ74850217A NZ748502A NZ 748502 A NZ748502 A NZ 748502A NZ 748502 A NZ748502 A NZ 748502A NZ 74850217 A NZ74850217 A NZ 74850217A NZ 748502 A NZ748502 A NZ 748502A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methyl
- oxaborole
- valinate
- dihydrobenzo
- carbonyl
- Prior art date
Links
- OHENQANLQNOMAO-UHFFFAOYSA-N oxaborole Chemical class O1B=CC=C1 OHENQANLQNOMAO-UHFFFAOYSA-N 0.000 title 1
- -1 oxaborole ester compounds Chemical class 0.000 abstract 13
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- AUDHLQWLNVOGDC-IBGZPJMESA-N AN11736 Chemical compound CC(C)[C@H](NC(=O)C1=CC=C2COB(O)C2=C1C)C(=O)OCC1=CC=C(F)C=C1 AUDHLQWLNVOGDC-IBGZPJMESA-N 0.000 abstract 2
- 206010001935 American trypanosomiasis Diseases 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 208000024699 Chagas disease Diseases 0.000 abstract 1
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 241000222712 Kinetoplastida Species 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 241000223109 Trypanosoma cruzi Species 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000003495 flagella Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Trypanosomatids are a group of kinetoplastid protozoa distinguished by having only a single flagellum. Trypanosomatids are responsible for diseases such as South American trypanosomiasis (Chagas Disease) and African Animal Trypanosomosis (AAT). Trypanosomosis has a major economic impact on cattle production in Africa and, if untreated, generally results in chronic illness with high mortality. In the absence of vaccines, control of this disease has for long been focused on chemotherapy and vector control. The present invention provides certain oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as African Animal Trypanosomosis. In particular, the present invention provides a compound selected from the group consisting of: (6-(Trifluoromethyl)pyridin-3-yl)methyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; 4-Fluorobenzyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; and, 4,4- Difluorocyclohexyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; Tetrahydro-2H-pyran-4-yl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; and, a pharmaceutically acceptable salt thereof. Also provided is the use of a compound selected from the group consisting of: (6-(Trifluoromethyl)pyridin-3-yl)methyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; 4-Fluorobenzyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; and, 4,4- Difluorocyclohexyl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; Tetrahydro-2H-pyran-4-yl (1-hydroxy-7-methyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonyl)-L-valinate; and, a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a parasitic infection in a subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662335565P | 2016-05-12 | 2016-05-12 | |
NZ746906A NZ746906A (en) | 2016-05-12 | 2017-05-01 | Oxaborole esters and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ748502A true NZ748502A (en) | 2020-06-26 |
Family
ID=72291342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ748502A NZ748502A (en) | 2016-05-12 | 2017-05-01 | Oxaborole esters and uses thereof |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ748502A (en) |
-
2017
- 2017-05-01 NZ NZ748502A patent/NZ748502A/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002204A1 (en) | HIV inhibitor compounds. | |
CL2020000886A1 (en) | 1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors. | |
MX2019012884A (en) | Combination therapy. | |
MX2020001757A (en) | Compounds, salts thereof and methods for treatment of diseases. | |
PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
EA201691803A1 (en) | HUMAN PLASMA KALLIKREIN INHIBITORS | |
PH12017500829A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
NZ700761A (en) | Salt form of a human histone methyltransferase ezh2 inhibitor | |
BR112019006047A2 (en) | compounds, one or two or more compounds, pharmaceutically acceptable salt, methanesulfonate salt, ret kinase inhibitor, medicament, uses of the compound and a compound, methods for treating or preventing cancer and for treating or preventing cancer in an individual, and, composition pharmaceutical | |
PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
PH12016502103A1 (en) | Novel disubstituted 1,2, 4-triazine compound | |
MX2014004814A (en) | Compounds and methods for enhancing innate immune responses. | |
BR112019001457A2 (en) | treatment and prevention of sleep disorders | |
PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
JOP20190233A1 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
ZA201901168B (en) | Novel compounds for treating parasitic disease | |
WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
EA035519B9 (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
PH12018501646A1 (en) | Compositions and methods for treating infections | |
MX2018011592A (en) | Compound having mutant idh inhibitory activity, preparation method and use thereof. | |
MX2019006942A (en) | Non-peptide oxytocin receptor agonists. | |
MX2022007315A (en) | Sustained release olanzapine formulations. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2022 BY THOMSON REUTERS Effective date: 20210403 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2023 BY THOMSON REUTERS Effective date: 20220402 |
|
LAPS | Patent lapsed |